These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2138064)

  • 21. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.
    Lancet; 1992 Jul; 340(8811):96-9. PubMed ID: 1352024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trials of ondansetron with high-dose cisplatin.
    Kris MG
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):23-7. PubMed ID: 1387247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors].
    Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA
    Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of SN-307 (ondansetron), given intravenously for the treatment of nausea and vomiting caused by anticancer drugs including cisplatin-open study].
    Ikeda M; Taguchi T; Ota K; Furue H; Niitani H; Tsukagoshi S; Ariyoshi Y; Akasaka Y; Ohta J; Suminaga M
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1905-14. PubMed ID: 1387776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of ondansetron against nausea and vomiting caused by dacarbazine-containing chemotherapy.
    Legha SS; Hodges C; Ring S
    Cancer; 1992 Oct; 70(7):2018-20. PubMed ID: 1388090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ondansetron is effective in decreasing postoperative nausea and vomiting.
    Dershwitz M; Rosow CE; Di Biase PM; Joslyn AF; Sanderson PE
    Clin Pharmacol Ther; 1992 Jul; 52(1):96-101. PubMed ID: 1385567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiemetic activity of ondansetron in cancer patients receiving non-cisplatin chemotherapy.
    Fraschini G
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):41-7. PubMed ID: 1387249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of ondansetron in paediatric patients: a review of three studies.
    Stevens RF
    Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ondansetron--the first of a new class of antiemetic agents.
    Chaffee BJ; Tankanow RM
    Clin Pharm; 1991 Jun; 10(6):430-46. PubMed ID: 1829668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups.
    Fortney JT; Gan TJ; Graczyk S; Wetchler B; Melson T; Khalil S; McKenzie R; Parrillo S; Glass PS; Moote C; Wermeling D; Parasuraman TV; Duncan B; Creed MR
    Anesth Analg; 1998 Apr; 86(4):731-8. PubMed ID: 9539593
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
    Slabý J; Trnený M; Procházka B; Klener P
    Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for combination antiemetic therapy and strategies for the use of ondansetron in combinations.
    Kris MG
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):61-6. PubMed ID: 1387252
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).
    Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R
    Oncology; 1991; 48(5):403-5. PubMed ID: 1836058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
    Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL
    Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I and other dose-ranging studies of ondansetron.
    Grunberg SM
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):16-22. PubMed ID: 1387246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.